Neuro-Oncology

Neuro-oncology has been reshaped by the FDA approval of vorasidenib for IDH-mutant grade 2 gliomas (INDIGO trial), shifting practice toward earlier molecular-targeted intervention and away from immediate chemoradiation. GCNN 2027 will examine the maturing CAR-T pipeline for glioblastoma — including GD2, EGFRvIII and IL-13Ra2 constructs and dual-target intrathecal delivery — alongside tumor treating fields (Optune) integration and the disappointing immune checkpoint inhibitor signal in GBM. The track also covers BRAF/MEK inhibition in pediatric low-grade glioma, ANG1005 and HER2-ADCs for leptomeningeal disease, and modern stereotactic radiosurgery for brain metastases with neurocognitive sparing.